Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.

West China Hospital (Other)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

A randomized, prospective phase II trial was conducted to explore the timing of radiotherapy intervention in combination with chemotherapy and immunotherap in order to provide an effective treatment for patients with advanced esophageal squamous carcinoma with oligometastases.

Condition or Disease Intervention/Treatment Phase
  • Radiation: simultaneous with radiotherapy
  • Radiation: synchronous with radiotherapy
Phase 2

Study Design

Study Type:
Anticipated Enrollment :
63 participants
Intervention Model:
Parallel Assignment
Intervention Model Description:
A randomized, prospective phase II trial.A randomized, prospective phase II trial.
Single (Outcomes Assessor)
Primary Purpose:
Official Title:
Camrelizumab Plus Chemotherapy in Combination With Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases: a Randomized Controlled Phase II Clinical Study
Anticipated Study Start Date :
Nov 30, 2023
Anticipated Primary Completion Date :
Nov 30, 2025
Anticipated Study Completion Date :
Nov 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Simultaneous radiotherapy group

Radiation: simultaneous with radiotherapy
Chemotherapy combined with immunotherapy simultaneous with radiotherapy

Active Comparator: Sequential radiotherapy group

Radiation: synchronous with radiotherapy
Chemotherapy combined with immunotherapy synchronous with radiotherapy

Outcome Measures

Primary Outcome Measures

  1. Progression-Free Survival (PFS) [12 months]

    Progression-free survival will be measured as time to either progression or death.

Secondary Outcome Measures

  1. Overall survival (OS) [12 months]

    Overall survival will be measured as time to death from any cause.

  2. Disease Control Rate (DCR) [12 months]

    The DCR was defined as the proportion of patients with the best efficacy (complete response or partial response or stable disease).

  3. Objective response rate (ORR) [12 months]

    Defined as the response to treatment as assessed by the investigator based on the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) criteria, containing cases of complete response, and partial response.

  4. Adverse events [12 months.]

    toxicity values caused by treatment.

Eligibility Criteria


Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Aged 18-75 years old, male or female;

  • Patients with pathologically diagnosed esophageal squamous cell carcinoma;

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and <10% weight loss within six months;

  • Patients with distant organ metastasis or nonregional lymph node metastasis, or distant organ/nonregional lymph node metastasis with regional lymph node metastasis, as defined by the AJCC 8th edition;

  • All positive regional lymph nodes were counted as one lesion, and adjacent metastatic nonregional lymph nodes could be treated as one lesion;

  • All metastases must be amenable to local radiotherapy;

  • 5 or fewer metastatic lesions including tumor beds and recurrent anastomoses, ≤ 4 metastatic lesions in any organ system, and a maximum lesion diameter ≤ 5 cm;

  • not including fading lesions during prior therapy (i.e., no longer visible on CT or metabolically active eliminated on PET-CT);

  • All metastases have not received local treatment such as radiotherapy, surgery, radiofrequency ablation prior to enrollment (Lesions located in the area of prior radiotherapy may be considered target lesions if progression is confirmed and considered measurable according to RECIST 1.1);

  • Measurable lesions ≥1 cm (maximum diameter) determined by CT or MRI, or ≥2 cm by other radiologic techniques, according to RECIST criteria;

  • Expected survival time of at least 12 weeks;

  • No previous surgery, chemotherapy, radiation therapy or immunotherapy for any cancer within the past 6 months;

  • Laboratory test indicators meet the following criteria:

①Bone marrow function: hemoglobin (Hb) ≥80g/L; white blood cell count (WBC) ≥lower limit of normal; absolute neutrophil count (ANC) ≥1.5×10^9 /L; platelet count ≥80×109 /L;

②Renal function: Cr ≤ ULN (upper limit of normal) × 1.5, endogenous creatinine clearance (Ccr) ≥ 45 ml/min;

③Liver function: total bilirubin ≤ ULN × 1.5; ALT and AST ≤ ULN × 2.5; (if there is liver metastasis, total bilirubin is not higher than 3 times the upper limit of normal, and transaminases are not higher than 5 times the upper limit of normal);

④Coagulation function: international normalized ratio of prothrombin time ≤ ULN × 1.5, and partial thromboplastin time within the normal value;

  • Females of child-bearing potential agree to use contraception during the study period and for 6 months after the completion of the study; patients who have had a negative serum or urine pregnancy test within seven days prior to enrollment in the study and who are not breastfeeding; and males agreeing to use contraception during the study period and for 6 months after the completion of the study;

  • Subjects who can understand the study situation and voluntarily sign the informed consent form;

  • Patients are expected to be compliant and able to follow up on efficacy and adverse events according to protocol requirements.

Exclusion Criteria:
  • Metastases with faint borders making radiotherapy treatment infeasible; metastases located within 3 cm of previously irradiated structures;

  • Poor nutritional status with a BMI < 18.5 Kg/m^2, if symptomatic nutritional support was corrected prior to randomization to group, enrollment may be considered after evaluation by the principal investigator;

  • Severe impairment of lung function.

  • patients with an esophageal mediastinal fistula and/or esophagotracheal fistula prior to treatment or at risk of invasion of vital vessels with lethal bleeding;

  • Diagnosis of other malignant tumors (except carcinoma in situ, basal cell carcinoma, etc.) within the previous 5 years;

  • Presence of any active autoimmune disease or history of autoimmune disease; immunodeficiency, active tuberculosis, hepatitis B ( hepatitis B virus titer HBV-DNA <500 IU/ml after treatment and if liver function is normal will be allowed), or positive test for hepatitis C virus.

  • Presence of hereditary or acquired bleeding and thrombotic tendencies;

  • Treatment with immunosuppressive drugs or corticosteroids (> 10 mg prednisone or equivalent per day) within 14 days prior to enrollment; patients are allowed to receive steroid therapy to control CNS-related symptoms, but the dose must ≤ 5 mg per day of dexamethasone (or equivalent); in the absence of an active autoimmune disease, inhaled or topical steroids and adrenal gland replacement dosing are acceptable; alternative therapies (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are permitted; patients with experimental medications that require premedication with corticosteroids are not restricted;

  • Allergic reaction to any of the study drugs or contraindication to radiotherapy;

  • Participation in another clinical trial within 30 days prior to enrollment;

  • Individuals considered by the investigator to be unsuitable for enrollment.

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • West China Hospital


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Ting Liu, Clinical Investigator, West China Hospital Identifier:
Other Study ID Numbers:
  • WestChinaHS
First Posted:
Nov 22, 2023
Last Update Posted:
Nov 22, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 22, 2023